122 related articles for article (PubMed ID: 36399552)
21. H
Takei J; Kaneko MK; Ohishi T; Kawada M; Harada H; Kato Y
Exp Ther Med; 2020 Aug; 20(2):846-853. PubMed ID: 32765652
[TBL] [Abstract][Full Text] [Related]
22. Establishment of P38Bf, a Core-Fucose-Deficient Mouse-Canine Chimeric Antibody Against Dog Podoplanin.
Kato Y; Mizuno T; Yamada S; Nakamura T; Itai S; Yanaka M; Sano M; Kaneko MK
Monoclon Antib Immunodiagn Immunother; 2018 Nov; 37(5):218-223. PubMed ID: 30362926
[TBL] [Abstract][Full Text] [Related]
23. Antibody-Drug Conjugates Using Mouse-Canine Chimeric Anti-Dog Podoplanin Antibody Exerts Antitumor Activity in a Mouse Xenograft Model.
Kato Y; Ito Y; Ohishi T; Kawada M; Nakamura T; Sayama Y; Sano M; Asano T; Yanaka M; Okamoto S; Handa S; Komatsu Y; Takei J; Kaneko MK
Monoclon Antib Immunodiagn Immunother; 2020 Apr; 39(2):37-44. PubMed ID: 32182186
[TBL] [Abstract][Full Text] [Related]
24. ChLpMab-23: Cancer-Specific Human-Mouse Chimeric Anti-Podoplanin Antibody Exhibits Antitumor Activity via Antibody-Dependent Cellular Cytotoxicity.
Kaneko MK; Nakamura T; Kunita A; Fukayama M; Abe S; Nishioka Y; Yamada S; Yanaka M; Saidoh N; Yoshida K; Fujii Y; Ogasawara S; Kato Y
Monoclon Antib Immunodiagn Immunother; 2017 Jun; 36(3):104-112. PubMed ID: 28504613
[TBL] [Abstract][Full Text] [Related]
25. The mouse-canine chimeric anti-dog podoplanin antibody P38B exerts antitumor activity in mouse xenograft models.
Kato Y; Ohishi T; Kawada M; Maekawa N; Konnai S; Itai S; Yamada S; Kaneko MK
Biochem Biophys Rep; 2019 Mar; 17():23-26. PubMed ID: 30519645
[TBL] [Abstract][Full Text] [Related]
26. A defucosylated anti‑CD44 monoclonal antibody 5‑mG2a‑f exerts antitumor effects in mouse xenograft models of oral squamous cell carcinoma.
Takei J; Kaneko MK; Ohishi T; Hosono H; Nakamura T; Yanaka M; Sano M; Asano T; Sayama Y; Kawada M; Harada H; Kato Y
Oncol Rep; 2020 Nov; 44(5):1949-1960. PubMed ID: 33000243
[TBL] [Abstract][Full Text] [Related]
27. Antitumor activities of a defucosylated anti‑EpCAM monoclonal antibody in colorectal carcinoma xenograft models.
Li G; Suzuki H; Ohishi T; Asano T; Tanaka T; Yanaka M; Nakamura T; Yoshikawa T; Kawada M; Kaneko MK; Kato Y
Int J Mol Med; 2023 Feb; 51(2):. PubMed ID: 36660940
[TBL] [Abstract][Full Text] [Related]
28. Establishment of a Novel Cancer-Specific Anti-HER2 Monoclonal Antibody H
Kaneko MK; Suzuki H; Kato Y
Monoclon Antib Immunodiagn Immunother; 2024 Apr; 43(2):35-43. PubMed ID: 38563783
[TBL] [Abstract][Full Text] [Related]
29. Structural and functional characterization of MBS301, an afucosylated bispecific anti-HER2 antibody.
Huang S; Li F; Liu H; Ye P; Fan X; Yuan X; Wu Z; Chen J; Jin C; Shen B; Feng J; Zhang B
MAbs; 2018; 10(6):864-875. PubMed ID: 30081724
[TBL] [Abstract][Full Text] [Related]
30. Antitumor activity of chLpMab-2, a human-mouse chimeric cancer-specific antihuman podoplanin antibody, via antibody-dependent cellular cytotoxicity.
Kaneko MK; Yamada S; Nakamura T; Abe S; Nishioka Y; Kunita A; Fukayama M; Fujii Y; Ogasawara S; Kato Y
Cancer Med; 2017 Apr; 6(4):768-777. PubMed ID: 28332312
[TBL] [Abstract][Full Text] [Related]
31. Antiglycopeptide Mouse Monoclonal Antibody LpMab-21 Exerts Antitumor Activity Against Human Podoplanin Through Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity.
Kato Y; Kunita A; Fukayama M; Abe S; Nishioka Y; Uchida H; Tahara H; Yamada S; Yanaka M; Nakamura T; Saidoh N; Yoshida K; Fujii Y; Honma R; Takagi M; Ogasawara S; Murata T; Kaneko MK
Monoclon Antib Immunodiagn Immunother; 2017 Feb; 36(1):20-24. PubMed ID: 28234556
[TBL] [Abstract][Full Text] [Related]
32. Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties.
Nordstrom JL; Gorlatov S; Zhang W; Yang Y; Huang L; Burke S; Li H; Ciccarone V; Zhang T; Stavenhagen J; Koenig S; Stewart SJ; Moore PA; Johnson S; Bonvini E
Breast Cancer Res; 2011; 13(6):R123. PubMed ID: 22129105
[TBL] [Abstract][Full Text] [Related]
33. An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity.
Weisser NE; Sanches M; Escobar-Cabrera E; O'Toole J; Whalen E; Chan PWY; Wickman G; Abraham L; Choi K; Harbourne B; Samiotakis A; Rojas AH; Volkers G; Wong J; Atkinson CE; Baardsnes J; Worrall LJ; Browman D; Smith EE; Baichoo P; Cheng CW; Guedia J; Kang S; Mukhopadhyay A; Newhook L; Ohrn A; Raghunatha P; Zago-Schmitt M; Schrag JD; Smith J; Zwierzchowski P; Scurll JM; Fung V; Black S; Strynadka NCJ; Gold MR; Presta LG; Ng G; Dixit S
Nat Commun; 2023 Mar; 14(1):1394. PubMed ID: 36914633
[TBL] [Abstract][Full Text] [Related]
34. Antitumor effect of novel anti-podoplanin antibody NZ-12 against malignant pleural mesothelioma in an orthotopic xenograft model.
Abe S; Kaneko MK; Tsuchihashi Y; Izumi T; Ogasawara S; Okada N; Sato C; Tobiume M; Otsuka K; Miyamoto L; Tsuchiya K; Kawazoe K; Kato Y; Nishioka Y
Cancer Sci; 2016 Sep; 107(9):1198-205. PubMed ID: 27294401
[TBL] [Abstract][Full Text] [Related]
35. GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma.
Park JA; Cheung NV
J Hematol Oncol; 2020 Dec; 13(1):172. PubMed ID: 33303017
[TBL] [Abstract][Full Text] [Related]
36. Antitumor activity of a monoclonal antibody targeting major histocompatibility complex class I-Her2 peptide complexes.
Jain R; Rawat A; Verma B; Markiewski MM; Weidanz JA
J Natl Cancer Inst; 2013 Feb; 105(3):202-18. PubMed ID: 23300219
[TBL] [Abstract][Full Text] [Related]
37. An anti‑TROP2 monoclonal antibody TrMab‑6 exerts antitumor activity in breast cancer mouse xenograft models.
Tanaka T; Ohishi T; Asano T; Takei J; Nanamiya R; Hosono H; Sano M; Harada H; Kawada M; Kaneko MK; Kato Y
Oncol Rep; 2021 Jul; 46(1):. PubMed ID: 34013368
[TBL] [Abstract][Full Text] [Related]
38. A Cancer-Specific Monoclonal Antibody against Podocalyxin Exerted Antitumor Activities in Pancreatic Cancer Xenografts.
Suzuki H; Ohishi T; Tanaka T; Kaneko MK; Kato Y
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203331
[TBL] [Abstract][Full Text] [Related]
39. Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma.
Niwa R; Shoji-Hosaka E; Sakurada M; Shinkawa T; Uchida K; Nakamura K; Matsushima K; Ueda R; Hanai N; Shitara K
Cancer Res; 2004 Mar; 64(6):2127-33. PubMed ID: 15026353
[TBL] [Abstract][Full Text] [Related]
40. Locally misfolded HER2 expressed on cancer cells is a promising target for development of cancer-specific antibodies.
Arimori T; Mihara E; Suzuki H; Ohishi T; Tanaka T; Kaneko MK; Takagi J; Kato Y
Structure; 2024 May; 32(5):536-549.e5. PubMed ID: 38460519
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
